痛风促尿酸排泄治疗的尿路结石发生率与风险:系统评价与荟萃分析
促尿酸排泄治疗者尿路结石合并发生率为3.35%(95%CI 2.03-4.92),合并风险比(vs未使用促尿酸排泄者)为1.63(95%CI 1.33-2.00,P=0.001)。作者认为尿路结石是促尿酸排泄治疗的常见副作用,但因异质性和偏倚,证据质量为低至中等。
要点
- 促尿酸排泄治疗者尿路结石合并发生率为3.35%(95%CI 2.03-4.92)。
- 苯溴马隆(10项研究)为3.92%(95%CI 1.89-6.52),Lesinurad(6项研究)为3.08%(95%CI 1.38-5.38)。
- 促尿酸排泄治疗者 vs 未使用促尿酸排泄者(其他ULT和/或安慰剂)的合并风险比为1.63(95%CI 1.33-2.00,P=0.001)。
核心结论
- 尿路结石是促尿酸排泄治疗的常见副作用,但证据质量因显著异质性和偏倚为低至中等。
- 促尿酸排泄治疗者尿路结石合并发生率为3.35%(95%CI 2.03-4.92)。
- 促尿酸排泄治疗者 vs 未使用促尿酸排泄者(其他ULT和/或安慰剂)的合并风险比为1.63(95%CI 1.33-2.00,P=0.001)。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase、Cochrane Library、Web of Science和ClinicalTrials.gov,检索日期2023年5月16日(更新至2024年5月10日)。
- 纳入评估痛风成人接受促尿酸排泄治疗后尿路结石发生率和/或风险的RCT和队列研究(可含或不含非促尿酸排泄ULT对照组)。
- 排除其他设计及仅涉及无症状高尿酸血症人群的研究。
- 采用随机效应模型计算合并发生率和风险估计,并对所有纳入研究进行偏倚风险评估。
主要发现
- 促尿酸排泄治疗者尿路结石合并发生率为3.35%(95%CI 2.03-4.92)。
- 苯溴马隆(10项研究)尿路结石发生率为3.92%(95%CI 1.89-6.52),Lesinurad(6项研究)为3.08%(95%CI 1.38-5.38)。
- 按研究设计,10项RCT的合并发生率为2.87%(95%CI 1.30-4.93),13项队列研究为3.93%(95%CI 1.95-6.44)。
- 促尿酸排泄治疗者 vs 未使用促尿酸排泄者(其他ULT和/或安慰剂)(9项研究)的尿路结石合并风险比为1.63(95%CI 1.33-2.00,P=0.001)。
关键数值与推荐
- 促尿酸排泄治疗者尿路结石合并发生率为3.35%(95%CI 2.03-4.92)。
- 苯溴马隆(10项研究)为3.92%(95%CI 1.89-6.52),Lesinurad(6项研究)为3.08%(95%CI 1.38-5.38)。
- RCT(10项)合并发生率为2.87%(95%CI 1.30-4.93),队列研究(13项)为3.93%(95%CI 1.95-6.44)。
- 促尿酸排泄治疗者 vs 未使用促尿酸排泄者(其他ULT和/或安慰剂)(9项研究)的合并风险比为1.63(95%CI 1.33-2.00,P=0.001)。
临床怎么用
- 促尿酸排泄治疗的尿路结石发生率和相关风险估计可用于痛风管理中更知情的共同治疗决策。
- 需进一步研究识别最高风险人群及可能从额外干预(如尿液碱化)中获益的人群。
局限性
- 证据质量因显著异质性和偏倚为低至中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the incidence and risk of nephrolithiasis in people receiving uricosuric therapies for gout. METHODS: A search was conducted using MEDLINE, Embase, Cochrane Library, Web of Science and Clinical Trials.gov electronic databases on 16 May 2023 (updated 10 May 2024). Randomized controlled trials (RCTs) and cohort studies assessing the incidence and/or risk of nephrolithiasis in adults with gout treated with uricosuric therapies were included (with or without a non-uricosuric urate-lowering therapy [ULT] comparator group). Other designs and studies involving people with asymptomatic hyperuricaemia only were excluded. A random-effects model was used to calculate pooled incidence and risk estimates. Risk of bias assessments were performed for all included studies. RESULTS: Twenty-three studies (10 RCTs, 13 cohort studies) were included in the meta-analysis (n = 78 042 participants, 15 385 received a uricosuric). The pooled incidence of nephrolithiasis amongst participants taking uricosuric therapies was 3.35% (95% CI 2.03-4.92) (Benzbromarone [10 studies] 3.92% [1.89-6.52], Lesinurad [6 studies] 3.08% [1.38-5.38]). Pooled incidence by study design was 2.87% (95% CI 1.30-4.93) in 10 RCTs and 3.93% (1.95-6.44) in 13 cohort studies. The pooled risk ratio for nephrolithiasis in participants taking uricosuric therapies vs participants not taking a uricosuric (other ULT and/or placebo) (nine studies) was 1.63 (95% CI 1.33-2.00, P = 0.001). CONCLUSION: Nephrolithiasis is a common side effect of uricosuric therapies, although the quality of evidence for this is low-moderate due to significant heterogeneity and bias. Further research is required to identify those at highest risk, and who may benefit from additional interventions such as urinary alkalinization. Our estimates of incidence of nephrolithiasis and associated risk can lead to more informed shared treatment decisions in the management of gout.
引用
- Dahanayake C, Bajpai R, Lambie M, et al. Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Rheumatology (Oxford). 2026. PMID: 41165601. doi:10.1093/rheumatology/keaf577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。